Metsera
Metsera was a clinical-stage biotech that developed ultra-long-acting injectable peptide therapies, including monthly GLP-1 agonist berobenatide, for obesity and metabolic diseases. Founded April 2024, it was acquired by Pfizer in November 2025 for up to $10 billion.
- Company typePrivate
- Founded2024
- HeadquartersNew York, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Metsera does
Metsera was a New York-based clinical-stage biotechnology company founded in April 2024 that developed oral and injectable hormone therapies for obesity and related metabolic diseases. Its core technology centered on an ultra-long-acting injectable peptide platform designed to enable monthly dosing of GLP-1 receptor agonists, differentiating from the weekly-injection regimens marketed by Eli Lilly (Zepbound) and Novo Nordisk (Wegovy). The pipeline comprised four novel incretin and amylin programs, headlined by berobenatide (PF'3944), a monthly GLP-1 receptor agonist in Phase III development that demonstrated up to 15.9% body weight reduction at 32 weeks and 14.9% at 60 weeks in clinical trials, with first approvals targeted for 2028. PF'3944 (MET-097i), in Phase IIb, showed 12.3% placebo-adjusted weight loss at 28 weeks with weekly-to-monthly dosing transition, and amylin programs expanded the franchise beyond GLP-1 monotherapy.
Metsera's business model was R&D-driven rather than revenue-generating. The company launched with a $290 million financing led by ARCH Venture Partners and Population Health Partners in April 2024, followed by a $215 million round in November 2024 led by Venrock Healthcare Capital Partners and Wellington Management, with participation from SoftBank, Fidelity, Google Ventures, RA Capital, and others. There were no commercial customers, no product pricing, and no disclosed revenue; investor exit was pursued through strategic M&A. In November 2025, Pfizer acquired Metsera for approximately $7 billion upfront and up to $10 billion with contingent value rights, outbidding Novo Nordisk in a competitive auction. Post-acquisition, Metsera operates as a wholly-owned subsidiary of Pfizer, with its assets absorbed into Pfizer's obesity and metabolic disease franchise, including plans for approximately 20 pivotal clinical trial starts in 2026 across the Metsera portfolio.
Metsera firmographics
Firmographics- Name
- Metsera
- Legal name
- Metsera
- Website
- https://metsera.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Short description
- Metsera was a clinical-stage biotech that developed ultra-long-acting injectable peptide therapies, including monthly GLP-1 agonist berobenatide, for obesity and metabolic diseases. Founded April 2024, it was acquired by Pfizer in November 2025 for up to $10 billion.
- Ownership category
- akta.pro rank
Metsera industry classification
Industry- Product category
- Obesity Therapeutics
- akta.pro primary industry
- Enzyme Replacement & Metabolic Disorder Therapies (HLAIAIAB)
- akta.pro secondary industry
- Endocrine Hypertension & Neuroendocrine Disorders (HLAKADAN)
Keywords
Where Metsera is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Metsera business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
Revenue model
- R&D Pipeline Development: Pre-acquisition, Metsera was a clinical-stage biotech company developing obesity and metabolic disease medicines. The company raised $290 million at launch and was acquired by Pfizer in 2025 for approximately $10 billion (including contingent value rights), representing the primary exit mechanism for investors.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Metsera product offering
Product offeringCore offering
Metsera is a clinical-stage biopharmaceutical company developing a portfolio of novel injectable and oral hormone-based therapies (GLP-1 receptor agonists and amylin analogs) for obesity and metabolic diseases. Its pipeline includes late-stage candidates aimed at next-generation obesity treatment through ultra-long-acting peptides and oral formulations.
Product overview
Metsera was a clinical-stage biotechnology company focused on obesity and metabolic disease medicines. The company was acquired by Pfizer in November 2025 for approximately $10 billion. Metsera's key product was berobenatide (PF'3944), a GLP-1 receptor agonist with monthly dosing, along with other incretin and amylin programs. These assets are now part of Pfizer's obesity pipeline with potential approvals targeted for 2028.
Differentiator
Problem solved
Functional benefit
Products and services
- Berubenatide (MET-002) An ultra-long-acting GLP-1 receptor agonist developed for once-monthly or less frequent dosing in adults with obesity and overweight; in Phase III clinical development.
- MET-097i (PF-3944) A Phase II GLP-1 receptor agonist for obesity and overweight indications with the goal of differentiated dosing or efficacy profile.
- MET-233i A Phase I amylin analog designed as a hormone therapy for obesity and metabolic disease, intended to be used alone or in combination with GLP-1 agents.
- Amylin program pipeline A broader pipeline of amylin-based peptide candidates for obesity and metabolic disease, complementing the GLP-1 franchise.
- Ultra-long-acting GLP-1 platform A proprietary peptide engineering platform enabling ultra-long-acting GLP-1 receptor agonists with extended dosing intervals.
Quantifiable outcome
- 15.9% body weight reduction at 32 weeks with monthly berobenatide dosing
- +2 more outcomes
Companies that use Metsera
Customer profileNamed customers1 record
Segments2 records
Metsera technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Metsera partnerships and signals
Strategic signalScale indicators5 records
Recent moves6 records
Expansion highlights6 records
Metsera competitors and assessment
Company assessmentDirect peers
- Viking Therapeutics: Clinical-stage biotech developing VK2735, a dual GLP-1/GIP agonist for obesity in Phase 2/3 development. Highly comparable as a small-cap, clinical-stage obesity-focused biotech with novel incretin assets.
Broad incumbents
- Eli Lilly: Developer and commercializer of tirzepatide (Zepbound/Mounjaro), the leading GLP-1/GIP obesity therapy. Direct competitor to Metsera's berobenatide in the obesity indication and the dominant incumbent in the GLP-1 space.
- Novo Nordisk: Maker of semaglutide (Wegovy/Ozempic), the foundational GLP-1 obesity franchise. Direct competitor to berobenatide and the other bidder in the Pfizer-Metsera acquisition auction.
- Amgen: Large biopharma developing MariTide (AMG 133), a GLP-1/amylin combination for obesity in Phase 3. Directly comparable as a major biopharma with late-stage obesity pipeline assets.
- AstraZeneca: Large biopharma with a growing obesity pipeline including oral GLP-1 candidates and partnerships (e.g., Eccogene). Comparable as a major pharma making strategic entry into the obesity/metabolic disease space.
- Roche: Large biopharma with an emerging obesity pipeline (e.g., CT-388 partnership with Carmot). Comparable as a major incumbent seeking differentiated entry into the obesity market similar to Pfizer's Metsera strategy.
Emerging players
- Structure Therapeutics: Clinical-stage biotech developing oral small-molecule GLP-1 agonists (GSBR-1290) for obesity and diabetes. Comparable as an emerging obesity-focused biotech with differentiated mechanism (oral vs. injectable) addressing adherence.
- Zealand Pharma: Clinical-stage biotech developing petrelintide (amylin analog) for obesity, with major partnership with Boehringer Ingelheim. Comparable through its amylin-focused obesity pipeline, mirroring Metsera's amylin program strategy.
- Altimmune: Clinical-stage biotech developing pemvidutide, a GLP-1/glucagon dual agonist for obesity in Phase 2. Comparable as a smaller-cap, clinical-stage obesity biotech pursuing differentiated incretin mechanisms.
- Carmot Therapeutics: Clinical-stage biotech developing incretin-based obesity therapies (acquired by Roche in 2024). Comparable as a clinical-stage biotech with differentiated GLP-1 assets that was acquired by a major pharma for its obesity pipeline.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Metsera social profiles
Digital presenceMetsera financial estimates
Financial estimateRevenue estimate
Valuation estimate
Metsera leadership team
Management profileNumber of profiles
Metsera funding detail
Funding detailFunding overview
Funding rounds3 records
Investors17 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Metsera M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Metsera
What does Metsera do?
Metsera is a clinical-stage biopharmaceutical company developing a portfolio of novel injectable and oral hormone-based therapies (GLP-1 receptor agonists and amylin analogs) for obesity and metabolic diseases. Its pipeline includes late-stage candidates aimed at next-generation obesity treatment through ultra-long-acting peptides and oral formulations.
Is Metsera a public or private company?
Metsera is a private company. It is classified as corporate owned and is currently acquired.
When was Metsera founded?
Metsera was founded in 2024. It employs 51 to 100 people.
Where is Metsera based?
Metsera is headquartered in New York, United States, in the North America region.
How does Metsera make money?
One revenue line is on record: R&D Pipeline Development.
Who are Metsera's main competitors?
Viking Therapeutics is listed as a direct peer. Broad incumbents are Eli Lilly, Novo Nordisk, Amgen, AstraZeneca and Roche. Emerging players are Structure Therapeutics, Zealand Pharma, Altimmune and Carmot Therapeutics.
Does Metsera have an API?
No public API is recorded for Metsera.
What industry is Metsera in?
Metsera's product category is Obesity Therapeutics. Its primary akta.pro industry code is HLAIAIAB, Enzyme Replacement & Metabolic Disorder Therapies, with a secondary code of HLAKADAN, Endocrine Hypertension & Neuroendocrine Disorders.